| Kaitlyn Branigan Brunner, DO | |
|
1850 E Park Ave, Ste 301, State College, PA 16803-6706 | |
| (814) 237-3470 | |
| (814) 237-2035 |
| Full Name | Kaitlyn Branigan Brunner |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 1850 E Park Ave, State College, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609149970 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | OS018124 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Nittany Medical Center | State college, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mount Nittany Medical Center Health Services Inc | 8426136797 | 196 |
News Archive
In this post on the Center for Global Development's (CGD) "Rethinking U.S. Foreign Assistance Blog," Jenny Ottenhoff, policy outreach associate at CGD, previews issues that may be raised when Secretary of State Hillary Rodham Clinton testifies before four congressional committees this week about President Obama's FY 2013 budget request for the State Department and USAID.
Walgreens today announced the official launch of a comprehensive customer loyalty program on Sunday, Sept. 16, offering customers ways to save, earn points and get rewarded for purchases, services and healthy behaviors.
The United States Preventive Services Task Force issues new recommendations for screening for BRCA1 and BRCA2 gene mutations in the Sept. 6, 2005, issue of Annals of Internal Medicine.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
A study published in the October issue of Anesthesiology analyzed the effectiveness of ultrasound examination in the diagnosis and treatment of critical care patients. In particular, the study looked at the ability of ultrasound to detect hidden anomalies, prompt urgent changes in therapy, induce further testing or interventions, and confirm or modify diagnoses.
› Verified 9 days ago
| Entity Name | Mount Nittany Medical Center Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164691499 PECOS PAC ID: 8426136797 Enrollment ID: O20081021000240 |
News Archive
In this post on the Center for Global Development's (CGD) "Rethinking U.S. Foreign Assistance Blog," Jenny Ottenhoff, policy outreach associate at CGD, previews issues that may be raised when Secretary of State Hillary Rodham Clinton testifies before four congressional committees this week about President Obama's FY 2013 budget request for the State Department and USAID.
Walgreens today announced the official launch of a comprehensive customer loyalty program on Sunday, Sept. 16, offering customers ways to save, earn points and get rewarded for purchases, services and healthy behaviors.
The United States Preventive Services Task Force issues new recommendations for screening for BRCA1 and BRCA2 gene mutations in the Sept. 6, 2005, issue of Annals of Internal Medicine.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
A study published in the October issue of Anesthesiology analyzed the effectiveness of ultrasound examination in the diagnosis and treatment of critical care patients. In particular, the study looked at the ability of ultrasound to detect hidden anomalies, prompt urgent changes in therapy, induce further testing or interventions, and confirm or modify diagnoses.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kaitlyn Branigan Brunner, DO 1850 E Park Ave, Ste 301, State College, PA 16803-6706 Ph: (814) 237-3470 | Kaitlyn Branigan Brunner, DO 1850 E Park Ave, Ste 301, State College, PA 16803-6706 Ph: (814) 237-3470 |
News Archive
In this post on the Center for Global Development's (CGD) "Rethinking U.S. Foreign Assistance Blog," Jenny Ottenhoff, policy outreach associate at CGD, previews issues that may be raised when Secretary of State Hillary Rodham Clinton testifies before four congressional committees this week about President Obama's FY 2013 budget request for the State Department and USAID.
Walgreens today announced the official launch of a comprehensive customer loyalty program on Sunday, Sept. 16, offering customers ways to save, earn points and get rewarded for purchases, services and healthy behaviors.
The United States Preventive Services Task Force issues new recommendations for screening for BRCA1 and BRCA2 gene mutations in the Sept. 6, 2005, issue of Annals of Internal Medicine.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
A study published in the October issue of Anesthesiology analyzed the effectiveness of ultrasound examination in the diagnosis and treatment of critical care patients. In particular, the study looked at the ability of ultrasound to detect hidden anomalies, prompt urgent changes in therapy, induce further testing or interventions, and confirm or modify diagnoses.
› Verified 9 days ago
Laura L. Stephenson, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1850 E Park Ave, Suite 301, State College, PA 16803 Phone: 814-237-3470 Fax: 814-237-2035 | |
Dr. Shreya M Patel, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave, Ste 301, State College, PA 16803 Phone: 814-237-3470 Fax: 814-237-2035 | |
Melanie M. Chaputa-cherry, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave, Suite 301, State College, PA 16803 Phone: 814-237-3470 Fax: 814-237-2035 | |
Samantha L Nguyen, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave Ste 301, State College, PA 16803 Phone: 814-237-3470 Fax: 814-237-2035 | |
J Frederick Doucette, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave, Suite 301, State College, PA 16803 Phone: 814-237-3470 Fax: 814-237-2035 | |
Joshua Kraft, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave Ste 301, State College, PA 16803 Phone: 814-237-3470 Fax: 814-237-2035 |